One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Lecanemab and donanemab slow down the early stages of the disease - which is the most common form of dementia. But Alzheimer's Research UK says the NHS is not ready to roll out the drugs ...

Some scientists have even started to look into whether period blood (which contains stem cells – very adaptable cells which ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. Research on ...

Nonetheless, Lilly has submitted donanemab to the US FDA under the ... Its cost-effectiveness deliberations for lecanemab arrive at a price range of between $8,500 and $20,600 for a year's ...

Mike, who is from Kent, said: "I feel more confident every day." Donanemab, made by Eli Lilly, works in the same way as lecanemab - developed by companies Eisai and Biogen - which created ...

Donanemab and Lecanemab for Early Alzheimer’s: What You Need to Know Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid ...

Donanemab works by removing a sticky protein ... We observed a similar narrative unfold this past summer when Leqembi (lecanemab) was approved by the British regulatory authority in August ...

Not only has medical journal The Lancet added two new risk factors for the condition (high LDL cholesterol and vision loss), but dementia-slowing drugs donanemab and lecanemab were approved for ...